Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM24 with Nivolumab in Advanced Solid Tumors
NCT04731467Phase 2Completed
- Sponsor
- FameWave
- Start
- Mar 2021
- Primary completion
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 3
01
Overview
A Phase 2 trial of cm-24 in solid tumor, pancreatic cancer (PC), non-small cell lung cancer (NSCLC), ovarian cancer, papillary thyroid cancer (PTC), sponsored by FameWave. Started Mar 2021; status: completed.
02
Drugs
cm-24
03
Conditions
solid tumorpancreatic cancer (PC)non-small cell lung cancer (NSCLC)ovarian cancerpapillary thyroid cancer (PTC)
Beyond the preview
Go deeper on NCT04731467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04731467.